518 related articles for article (PubMed ID: 29806620)
1. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
[TBL] [Abstract][Full Text] [Related]
3. A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
Hwang YC; Kim JH; Lee BW; Lee WJ
Diabetes Metab J; 2019 Dec; 43(6):898-905. PubMed ID: 31237132
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study.
Shimoda M; Mashiko A; Katakura Y; Sanada J; Fushimi Y; Obata A; Kimura T; Kohara K; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
Endocr J; 2021 Dec; 68(12):1455-1461. PubMed ID: 34334532
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
[TBL] [Abstract][Full Text] [Related]
8. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Maegawa H; Tobe K; Tabuchi H; Nakamura I; Uno S
Expert Opin Pharmacother; 2018 Mar; 19(4):327-336. PubMed ID: 29388470
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
[TBL] [Abstract][Full Text] [Related]
12. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
Nagai Y; Ohta A; Sada Y; Kato H; Tanaka Y
Expert Opin Pharmacother; 2017 Jan; 18(1):13-17. PubMed ID: 27841020
[TBL] [Abstract][Full Text] [Related]
13. Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
Ishihara H; Yamaguchi S; Sugitani T; Kosakai Y
Clin Drug Investig; 2019 Dec; 39(12):1213-1221. PubMed ID: 31552641
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
[TBL] [Abstract][Full Text] [Related]
15. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
J Diabetes Investig; 2021 Feb; 12(2):200-206. PubMed ID: 32623839
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
17. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
Fonseca VA; Ferrannini E; Wilding JP; Wilpshaar W; Dhanjal P; Ball G; Klasen S
J Diabetes Complications; 2013; 27(3):268-73. PubMed ID: 23276620
[TBL] [Abstract][Full Text] [Related]
18. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A; Sakatani T; Nakamura I; Akiyama N; Kazuta K; Ueyama E; Takahashi H; Kosakai Y
Endocr J; 2018 Jul; 65(7):693-705. PubMed ID: 29848902
[TBL] [Abstract][Full Text] [Related]
19. The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Okura T; Fujioka Y; Nakamura R; Kitao S; Ito Y; Anno M; Matsumoto K; Shoji K; Matsuzawa K; Izawa S; Okura H; Ueta E; Kato M; Imamura T; Taniguchi SI; Yamamoto K
Sci Rep; 2022 Feb; 12(1):1896. PubMed ID: 35115614
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
Ishihara H; Yamaguchi S; Nakao I; Okitsu A; Asahina S
Diabetes Obes Metab; 2016 Dec; 18(12):1207-1216. PubMed ID: 27436788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]